| Methods |
Multicentre RCT
3 arms
Quality score: D |
| Participants |
n = 249
Median age: 61
ECOG 2‐3: 34% |
| Interventions |
FAP: 5‐FU 300 mg/m² d 1,8,15,22; adriamycin 30 mg/m² d 1; cisplatin 100 mg/m² d 1, repeated at d 29
versus
FAT: 5‐FU 300 mg/m² d1‐5; adriamycin 30 mg/m² d 1; triazinate 250 mg/m² d 22‐24, repeated at d 36
versus
FAMe: 5‐FU 325 mg/m² d1‐5, adriamycin 40 mg/m² d 1, Semustine 110 mg/m² p.os d 1, repeated at d 71 |
| Outcomes |
Median survival
Response rates
Toxicity not classified according to WHO or NCI |
| Notes |
— |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not stated |
| Allocation concealment (selection bias) |
Unclear risk |
Not stated |
| Incomplete outcome data (attrition bias)
efficacy |
Unclear risk |
Not clear how many screened for eligibility and excluded |
| Incomplete outcome data (attrition bias)
safety |
Unclear risk |
Not clear how many screened for eligibility and excluded |
| Selective reporting (reporting bias) |
Unclear risk |
Toxicity not classified according to WHO or NCI |
| Other bias |
Unclear risk |
N/A |
| Blinded review of CT/MRI‐scans? |
Unclear risk |
Not stated |
